Semaglutide vs Tirzepatide: Which GLP-1 Is Right for You?

If you’ve been researching GLP-1 medications for weight loss, you’ve likely come across two options: semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (the active ingredient in Mounjaro and Zepbound). Both are highly effective — but they work differently, cost differently, and may suit different patients.

This guide explains what the science actually shows, what doctors consider when choosing between them, and how to think about your own situation.

How Each Medication Works

Semaglutide is a GLP-1 receptor agonist. It mimics a hormone your gut releases after eating — signaling your brain that you’re full, slowing stomach emptying, and reducing appetite. It also improves insulin sensitivity.

Tirzepatide is a dual GIP/GLP-1 receptor agonist. It works on two hormonal pathways simultaneously: GLP-1 (the same as semaglutide) and GIP (glucose-dependent insulinotropic polypeptide). This dual action appears to amplify the metabolic effects beyond what GLP-1 alone achieves.

In simple terms: tirzepatide hits two targets instead of one, which is why clinical trials have shown it produces somewhat greater average weight loss.

What the Research Shows

The SURMOUNT-1 trial of tirzepatide showed average weight loss of 20.9% of body weight at the highest dose (15mg) over 72 weeks in people without diabetes.

The STEP 1 trial of semaglutide showed average weight loss of 14.9% of body weight at the 2.4mg dose over 68 weeks in people without diabetes.

Both are dramatic improvements over older weight-loss medications. Both significantly outperform diet and exercise alone.

Important caveat: These are averages from clinical trials. Individual results vary significantly based on genetics, adherence, lifestyle, and other factors. Some patients lose more on semaglutide than the tirzepatide average — and vice versa.

Side Effect Profile

Both medications share similar side effects, primarily because of the overlapping GLP-1 mechanism:

Nausea — most common, especially when starting or increasing dose
Vomiting — typically mild and improves over time
Diarrhea or constipation — varies by patient
Fatigue — common in the first weeks
Reduced appetite — the desired effect, but can lead to insufficient nutrition if not managed

Does tirzepatide cause more side effects?

Clinical data suggests the side effect profiles are similar, though some patients report that the GIP component in tirzepatide causes slightly more nausea at equivalent doses. However, since tirzepatide also tends to produce stronger appetite suppression, many patients find the trade-off worthwhile.

The key to minimizing side effects for either medication is a slow, gradual dose escalation — which is standard practice at REMEVi.

Cost Comparison

Brand-name versions (Ozempic, Wegovy, Mounjaro, Zepbound) can cost $900–$1,400/month without insurance. Even with insurance, prior authorizations are often denied for weight loss indications.

Compounded versions made by FDA-registered pharmacies use the same active pharmaceutical ingredient at a fraction of the cost.

At REMEVi:

Compounded semaglutide starts at $169/month (all-inclusive intro month, then $279/month)
Compounded tirzepatide starts at $289/month (all-inclusive)

Both include physician evaluation, medication, free shipping, and bilingual care coordinator access — no hidden fees.

Who Should Consider Semaglutide?

Semaglutide tends to be the right starting point if:

You are new to GLP-1 therapy and want to start with a well-established option
Cost is a significant consideration
You have a history of sensitivity to new medications and prefer a more conservative approach
Your weight-loss goal is 10–20% of body weight

Who Should Consider Tirzepatide?

Tirzepatide may be the better fit if:

You have already tried semaglutide and reached a plateau
You have a higher BMI and are targeting more significant weight loss
You have type 2 diabetes or insulin resistance (tirzepatide has stronger glycemic effects)
You want to maximize average weight-loss outcomes from the start

The Decision Is Personal

The right medication depends on your full medical picture — not just the comparison chart. At REMEVi, every patient is evaluated by a licensed US physician who reviews your health history, current medications, BMI, metabolic markers, and goals before recommending a protocol.

If you’re unsure which to choose, you don’t have to figure it out alone. Your REMEVi care coordinator (available in English and Spanish) can walk you through the options before you even complete the intake form.

Ready to Get Started?

REMEVi offers compounded semaglutide starting at $169/month and compounded tirzepatide at $289/month — both all-inclusive with physician review, free shipping, and bilingual support.

The intake form takes 5 minutes. Physician review happens within 24 hours. Medication arrives within 5–7 business days.

Start your free consultation →

This article is for informational purposes only and does not constitute medical advice. Consult with a licensed physician — including through REMEVi’s telehealth platform — before starting any prescription medication.